Concordia Healthcare Corp (CXRX) is Initiated by Goldman to Neutral

Concordia Healthcare Corp (CXRX) was Initiated by Goldman to “Neutral”. Goldman advised their investors in a research report released on Jun 6, 2016.

On the company’s financial health, Concordia Healthcare Corp reported $1.35 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on May 13, 2016. Analyst had a consensus of $1.40. The company had revenue of $228.50 million for the quarter, compared to analysts expectations of $228.07 million. The company’s revenue was up 570.1% compared to the same quarter last year.

Concordia Healthcare Corp. is a Canada-based diverse healthcare company. The Company is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments which includes Legacy Pharmaceutical Division Concordia Pharmaceuticals Inc. which consists of 23 products including Nilandron for the treatment of metastatic prostate cancer; Dibenzyline for the treatment of pheochromocytoma; Lanoxin for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; Donnatal for the treatment of irritable bowel syndrome and Zonegran (zonisamide) for treatment of partial seizures in adults with epilepsy. Its Specialty Healthcare Distribution (SHD) Division Complete Medical Homecare is engaged in the distribution of medical supplies focused on diabetes and related conditions. Its Orphan Drugs Division Concordia Laboratories Inc. is engaged in the manufacture of PHOTOFRIN.

Concordia Healthcare Corp

Leave a Reply

Concordia Healthcare Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Concordia Healthcare Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.